Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: hautnah 2/2022

07.04.2022 | Fallbericht

Erythroderme Psoriasis nach COVID-19-Erkrankung

verfasst von: Jeta Demiri, Miriam Abdo, PD Dr. med. Athanasios Tsianakas

Erschienen in: hautnah | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Wir präsentieren einen klinischen Fall eines Patienten mit akut exazerbierter erythrodermer Plaquepsoriasis nach einer symptomatischen Infektion mit SARS-CoV‑2. Es sind bereits unterschiedliche Faktoren bekannt, die zu einer Exazerbation der Psoriasis führen können wie Medikamente oder Infektionen mit z. B. Streptokokken. Ein Zusammenhang zwischen Psoriasis und einer Infektion mit dem neuartigen Coronavirus SARS-CoV‑2 wurde v. a. in Fallberichten beschrieben, in denen eine medikamentöse Behandlung mit z. B. Hydroxychloroquin erfolgt war, ein bekannter Trigger der Psoriasis. In der Folge gab es auch einzelne Beschreibungen einer Exazerbation nach COVID-19 ohne medikamentösen Trigger, teils auch als pustulöse Psoriasisform. Unser Artikel zeigt erstmals einen Fall einer Psoriasiserythrodermie getriggert durch eine COVID-19-Erkrankung ohne offensichtlich zusätzlich medikamentösen Auslöser.
Literatur
1.
Zurück zum Zitat Rendon A, Schäkel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475 CrossRef Rendon A, Schäkel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475 CrossRef
2.
Zurück zum Zitat Balak DM, Hajdarbegovic E (2017) Drug-induced psoriasis: clinical perspectives. Psoriasis 7:87–94 CrossRef Balak DM, Hajdarbegovic E (2017) Drug-induced psoriasis: clinical perspectives. Psoriasis 7:87–94 CrossRef
3.
Zurück zum Zitat Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated?: Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3:32–38 PubMedPubMedCentral Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated?: Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3:32–38 PubMedPubMedCentral
4.
Zurück zum Zitat Visser MJE, Kell DB, Pretorius E (2019) Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol 9:7 CrossRef Visser MJE, Kell DB, Pretorius E (2019) Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol 9:7 CrossRef
5.
Zurück zum Zitat Mallon E, Bunker CB (2000) HIV-associated psoriasis. AIDS Patient Care STDS 14:239–246 CrossRef Mallon E, Bunker CB (2000) HIV-associated psoriasis. AIDS Patient Care STDS 14:239–246 CrossRef
6.
Zurück zum Zitat Kutlu Ö, Metin A (2020) A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther 33(4):e13383 PubMed Kutlu Ö, Metin A (2020) A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther 33(4):e13383 PubMed
7.
Zurück zum Zitat Ozaras R, Berk A, Ucar DH et al (2020) Covid-19 and exacerbation of psoriasis. Dermatol Ther 33(4):e13632 CrossRef Ozaras R, Berk A, Ucar DH et al (2020) Covid-19 and exacerbation of psoriasis. Dermatol Ther 33(4):e13632 CrossRef
8.
Zurück zum Zitat Nasiri S, Araghi F, Tabary M et al (2020) A challenging case of psoriasis flare-up after COVID-19 infection. J Dermatolog Treat 31(5):448–449 CrossRef Nasiri S, Araghi F, Tabary M et al (2020) A challenging case of psoriasis flare-up after COVID-19 infection. J Dermatolog Treat 31(5):448–449 CrossRef
9.
Zurück zum Zitat Elrazi A, Abdelaziz M, Joud A et al (2021) SARS-CoV‑2 and guttate psoriasis: a case report and review of literature. Clin Case Rep 9(7):e4568 Elrazi A, Abdelaziz M, Joud A et al (2021) SARS-CoV‑2 and guttate psoriasis: a case report and review of literature. Clin Case Rep 9(7):e4568
10.
Zurück zum Zitat Buhl T, Beissert S, Gaffal E et al (2020) COVID-19 und Auswirkungen auf dermatologische und allergologische Erkrankungen. J Dtsch Dermatol Ges 18(8):815–825 PubMedPubMedCentral Buhl T, Beissert S, Gaffal E et al (2020) COVID-19 und Auswirkungen auf dermatologische und allergologische Erkrankungen. J Dtsch Dermatol Ges 18(8):815–825 PubMedPubMedCentral
11.
Zurück zum Zitat Buszko M, Nita-Lazar A, Park J‑H et al (2021) (2021) Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol 22(4):404–411 CrossRef Buszko M, Nita-Lazar A, Park J‑H et al (2021) (2021) Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol 22(4):404–411 CrossRef
12.
Zurück zum Zitat Jamiolkowski D, Mühleisen B, Müller S et al (2020) SARS-CoV‑2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet 396(10251):598–599 CrossRef Jamiolkowski D, Mühleisen B, Müller S et al (2020) SARS-CoV‑2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet 396(10251):598–599 CrossRef
13.
Zurück zum Zitat Ragab D, Salah Eldin H, Taeimah M et al (2020) The COVID-19 Cytokine storm; what we know so far. Front Immunol 11:1446 CrossRef Ragab D, Salah Eldin H, Taeimah M et al (2020) The COVID-19 Cytokine storm; what we know so far. Front Immunol 11:1446 CrossRef
14.
Zurück zum Zitat Kutlu Ö, Metin A (2020) Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther 33:e13509 PubMed Kutlu Ö, Metin A (2020) Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther 33:e13509 PubMed
15.
Zurück zum Zitat Amerio P, Prignano F, Giuliani F et al (2020) COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatol Ther 33:e13434 CrossRef Amerio P, Prignano F, Giuliani F et al (2020) COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatol Ther 33:e13434 CrossRef
16.
Zurück zum Zitat Elmas ÖF, Demirbaş A, Kutlu Ö et al (2020) Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther 33(6):e13858 PubMed Elmas ÖF, Demirbaş A, Kutlu Ö et al (2020) Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther 33(6):e13858 PubMed
17.
Zurück zum Zitat Mahil SK, Dand N, Mason KJ et al (2021) Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 147(1):60–71 CrossRef Mahil SK, Dand N, Mason KJ et al (2021) Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 147(1):60–71 CrossRef
18.
Zurück zum Zitat de Wijs LEM, Joustra MM, Olydam JI et al (2021) COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data. J Eur Acad Dermatol Venereol 35(3):e173–e176 PubMed de Wijs LEM, Joustra MM, Olydam JI et al (2021) COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data. J Eur Acad Dermatol Venereol 35(3):e173–e176 PubMed
21.
Zurück zum Zitat Munguía-Calzada P, Drake-Monfort M, Armesto S et al (2020) Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center. Dermatol Ther 34(1):e14684 PubMedPubMedCentral Munguía-Calzada P, Drake-Monfort M, Armesto S et al (2020) Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center. Dermatol Ther 34(1):e14684 PubMedPubMedCentral
24.
Zurück zum Zitat Sachdeva M, Mufti A, Maliyar K et al (2020) Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol 83(2):579–586 CrossRef Sachdeva M, Mufti A, Maliyar K et al (2020) Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol 83(2):579–586 CrossRef
25.
Zurück zum Zitat Kara Polat A, Oguz Topal I, Karadag AS et al (2021) The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther 34(1):e14691 CrossRef Kara Polat A, Oguz Topal I, Karadag AS et al (2021) The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther 34(1):e14691 CrossRef
26.
Zurück zum Zitat Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367 CrossRef Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367 CrossRef
27.
Zurück zum Zitat Gravani A, Gaitanis G, Zioga A et al (2014) Synthetic antimalarial drugs and the triggering of psoriasis do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? Int J Dermatol 53(3):327–330 CrossRef Gravani A, Gaitanis G, Zioga A et al (2014) Synthetic antimalarial drugs and the triggering of psoriasis do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? Int J Dermatol 53(3):327–330 CrossRef
28.
Zurück zum Zitat Said A, Bock S, Lajqi T et al (2014) Chloroquine promotes IL-17 production by CD41 T cells via p38- dependent IL-23 release by monocyte-derived Langerhanslike cells. J Immunol 193(12):6135–6143 CrossRef Said A, Bock S, Lajqi T et al (2014) Chloroquine promotes IL-17 production by CD41 T cells via p38- dependent IL-23 release by monocyte-derived Langerhanslike cells. J Immunol 193(12):6135–6143 CrossRef
30.
Zurück zum Zitat Samotij D, Gawron E, Szczech J et al (2021) Acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis following COVID-19: a case report of a successful treatment with Infliximab in combination with Acitretin. Biologics 27(15):107–113 Samotij D, Gawron E, Szczech J et al (2021) Acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis following COVID-19: a case report of a successful treatment with Infliximab in combination with Acitretin. Biologics 27(15):107–113
31.
Zurück zum Zitat Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866 CrossRef Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866 CrossRef
32.
Zurück zum Zitat FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538 CrossRef FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538 CrossRef
Metadaten
Titel
Erythroderme Psoriasis nach COVID-19-Erkrankung
verfasst von
Jeta Demiri
Miriam Abdo
PD Dr. med. Athanasios Tsianakas
Publikationsdatum
07.04.2022
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 2/2022
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-022-00506-5